Clinical Trial

Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development

Recruiting
View on ClinicalTrials.gov →
Summary
Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-03-26; most recent amendment 2026-05-08.
Status change: Not Yet Recruiting → Recruiting 2022-09-01
Trial Details
NCT Number NCT04824053
Lead Sponsor Instituto de Investigación Sanitaria Aragón
Collaborators: Cooperativas Lacteas Unidas, Hospital Clínico Universitario Lozano Blesa
Conditions Colorectal Polyp
Enrollment 34 participants
Start Date 2022-02-28
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-12